Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas

Journal of Neuro-Oncology(2020)10.1007/s11060-020-03407-wSource: DataRank Database

Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas is a research paper published in Journal of Neuro-Oncology (2020). On theSindex it has a DataRank of 0.442. It has been cited 18 times.

N/A

0.442DataRank · unranked

Scored on demand from live citation data

Open Access18 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 1.80)OA: greenTopics (118)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.442

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (13)

Jingwen Yao ORCID,Jacob Schlossman ORCID,Catalina Raymond ORCID,Matthew Ji ORCID,Hiroyuki Tatekawa ORCID

Live enrichment

PubMed:31981013 OpenAlex:https://openalex.org/W3001709021

American Cancer Society

Grant: RSG-15-003-01-CCE

American Brain Tumor Association

Grant: ARC1700002

National Institutes of Health

Grant: 1P50CA211015-01A1

UCLA SPORE in Brain Cancer

National Institutes of Health

Grant: 1R21CA223757-01

Metabolic MRI for quantifying aerobic glycolysis and immune function in gliomas

Wellcome Trust

Grant: unidentified

unidentified

EPA

Grant: EP-C-15-003

NCI NIH HHS

Grant: P30 CA016042

NCI NIH HHS

Grant: P50 CA211015

NCI NIH HHS

Grant: R21 CA223757

Wellcome Trust

FWCI

1.80

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2024

greenLicense: Springer TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7080591

publisherhttp://link.springer.com/content/pdf/10.1007/s11060-020-03407-w.pdf

publisherhttp://link.springer.com/article/10.1007/s11060-020-03407-w/fulltext.html

journalhttps://doi.org/10.1007/s11060-020-03407-w

Fields of Study

Glioma Diagnosis and TreatmentBrain Metastases and TreatmentEpilepsy research and treatment0302 clinical medicine03 medical and health sciencesAdultAgedAged, 80 and overBrain NeoplasmsCell Transformation, NeoplasticDihydroxyphenylalanineFemaleGliomaHumansMagnetic Resonance ImagingMaleMiddle AgedPositron-Emission TomographySensitivity and SpecificitySurvival AnalysisTumor BurdenYoung Adult

MeSH Terms

AdultAgedAged, 80 and overBrain NeoplasmsCell Transformation, NeoplasticDihydroxyphenylalanineFemaleGliomaHumansMagnetic Resonance ImagingMaleMiddle AgedSensitivity and SpecificitySurvival AnalysisTumor BurdenPositron-Emission TomographyYoung Adult

Keywords

Fluid-attenuated inversion recoveryNuclear medicineMedicineGliomaProportional hazards modelPositron emission tomographyUnivariate analysisInternal medicineMagnetic resonance imagingRadiologyMultivariate analysisCancer researchMagnetic Resonance Imaging (mesh)MaleCell TransformationBiomedical Imaging (rcdc)Precision Medicine (rcdc)Glioma (mesh)80 and over80 and over (mesh)Dihydroxyphenylalanine (mesh)Precision Medicine32 Biomedical and Clinical Sciences (for-2020)Male (mesh)Neurosciences (rcdc)CancerCancer (rcdc)Aged, 80 and overHumans (mesh)Young Adult (mesh)Tumor Burden (mesh)Brain NeoplasmsBioengineering (rcdc)1112 Oncology and Carcinogenesis (for)Middle Aged3209 Neurosciences (for-2020)DihydroxyphenylalanineTumor Burden18F-FDOPA PETCell Transformation, Neoplastic4.2 Evaluation of markers and technologies (hrcs-rac)Biomedical ImagingFemaleSensitivity and Specificity (mesh)Brain Neoplasms (mesh)4.2 Evaluation of markers and technologiesMRIAdultF-18-FDOPA PETClinical SciencesOncology and CarcinogenesisPositron-Emission Tomography (mesh)610BioengineeringSensitivity and SpecificityRare Diseases (rcdc)Young AdultRare DiseasesMiddle Aged (mesh)Low grade glioma3211 Oncology and carcinogenesis (for-2020)HumansOncology & Carcinogenesis3202 Clinical Sciences (for-2020)AgedNeoplasticNeoplastic (mesh)Biomedical and Clinical SciencesAged (mesh)NeurosciencesSurvival Analysis (mesh)Cancer (hrcs-hc)Biomarker1109 Neurosciences (for)Survival AnalysisOncology & Carcinogenesis (science-metrix)Female (mesh)Positron-Emission TomographyAdult (mesh)

Sustainable Development Goals

SDG 0: Good health and well-being